Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

Wencheng Zhang; Cihui Yan; Xuan Gao; Xiaoxia Li; Fuliang Cao; Gang Zhao; Jingjing Zhao; Puchun Er; Tian Zhang; Xi Chen; Yuwen Wang; Yao Jiang; Quanren Wang; Baozhong Zhang; Dong Qian; Jun Wang; Dejun Zhou; Xiubao Ren; Zhentao Yu; Lujun Zhao; Zhiyong Yuan; Ping Wang; Qingsong Pang

doi:10.1002/onco.13797

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Radiotherapy plus camrelizumab had manageable toxicity and antitumor efficacy for locally advanced ESCC. Several biomarkers were associated with clinical benefit and deserve further study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2021) studied this question.

synapsesocial.com/papers/69d87ffd18b0ca7f91d17fe2 https://doi.org/10.1002/onco.13797

View Full Paper

Ask AI

Bookmark

Share

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading